The effect of glucosamine, chondroitin and harpagophytum procumbens on femoral hyaline cartilage thickness in patients with knee osteoarthritis– An MRI versus ultrasonography study by Vreju, Florentin Ananu et al.
Journal of Mind and Medical Sciences
Volume 6 | Issue 1 Article 25
2019
The effect of glucosamine, chondroitin and
harpagophytum procumbens on femoral hyaline
cartilage thickness in patients with knee
osteoarthritis– An MRI versus ultrasonography
study
Florentin Ananu Vreju
Craiova University of Medicine and Pharmacy, Department of Rheumatology, Craiova, Romania, florin_vreju@yahoo.com
Paulina Lucia Ciurea
Craiova University of Medicine and Pharmacy, Department of Rheumatology, Craiova, Romania
Anca Rosu
Craiova University of Medicine and Pharmacy, Craiova, Romania
Beatrice Andreea Chisalau
Craiova University of Medicine and Pharmacy, Craiova, Romania
Cristina Dorina Parvanescu
Craiova University of Medicine and Pharmacy, Craiova, Romania
This Research Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical
Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.
Recommended Citation
Vreju, Florentin Ananu; Ciurea, Paulina Lucia; Rosu, Anca; Chisalau, Beatrice Andreea; Parvanescu, Cristina Dorina; Firulescu, Sineta
Cristina; Turcu Stiolica, Adina; Barbulescu, Andreea Lili; Dinescu, Stefan Cristian; Dumitrescu, Cristiana Iulia; Dumitrascu, Roxana
Mihaela; Criveanu, Cristina; Radu, Lucretiu; Tusaliu, Mihai; and Dumitrescu, Daniela (2019) "The effect of glucosamine, chondroitin
and harpagophytum procumbens on femoral hyaline cartilage thickness in patients with knee osteoarthritis– An MRI versus
ultrasonography study," Journal of Mind and Medical Sciences: Vol. 6 : Iss. 1 , Article 25.
DOI: 10.22543/7674.61.P162168
Available at: https://scholar.valpo.edu/jmms/vol6/iss1/25
See next page for additional authors
Follow this and additional works at: https://scholar.valpo.edu/jmms
Part of the Biochemical Phenomena, Metabolism, and Nutrition Commons, Medical
Pharmacology Commons, Musculoskeletal, Neural, and Ocular Physiology Commons, Radiology
Commons, and the Rheumatology Commons
The effect of glucosamine, chondroitin and harpagophytum procumbens
on femoral hyaline cartilage thickness in patients with knee osteoarthritis–
An MRI versus ultrasonography study
Cover Page Footnote
This work was supported by a grant 966/2013 offered by Fiterman Pharma SRL
Authors
Florentin Ananu Vreju, Paulina Lucia Ciurea, Anca Rosu, Beatrice Andreea Chisalau, Cristina Dorina
Parvanescu, Sineta Cristina Firulescu, Adina Turcu Stiolica, Andreea Lili Barbulescu, Stefan Cristian Dinescu,
Cristiana Iulia Dumitrescu, Roxana Mihaela Dumitrascu, Cristina Criveanu, Lucretiu Radu, Mihai Tusaliu,
and Daniela Dumitrescu
This research article is available in Journal of Mind and Medical Sciences: https://scholar.valpo.edu/jmms/vol6/iss1/25
  
Copyright © 2019. All rights reserved 
https://scholar.valpo.edu/jmms/ 
https://proscholar.org/jmms/  
ISSN: 2392-7674 
 
 
J Mind Med Sci. 2019; 6(1): 162-168 
doi: 10.22543/7674.61.P162168 
 
   
 
 
*Corresponding author: Cristiana Iulia Dumitrescu, Craiova University of Medicine and Pharmacy, 
Department of Pharmacology,  2 Petru Rareş Street, Craiova, Romania 
E-mail: dumitrescu.cristiana@gmail.com  
To cite this article: Vreju FA, Ciurea PL, Chisalau BA, Parvanescu CD, Firulescu SC, Turcu-Stiolica A, 
Barbulescu AL, Dinescu SC, Dumitrescu CI, Cristina C, Radu L, Dumitrescu D. The effect of glucosamine, 
chondroitin and harpagophytum procumbens on femoral hyaline cartilage thickness in patients with knee 
osteoarthritis– An MRI versus ultrasonography study. J Mind Med Sci. 2019; 6(1): 162-168. DOI: 
10.22543/7674.61.P162168 
 
  
 
 
 
 
 
 
 
 
 
Received for publication: October 15, 2018 
Accepted: January 17, 2019 
Research article 
The effect of glucosamine, chondroitin and 
harpagophytum procumbens on femoral hyaline 
cartilage thickness in patients with knee 
osteoarthritis– An MRI versus ultrasonography 
study 
 
Florentin A. Vreju1, Paulina L. Ciurea1, Anca Rosu2, Beatrice A. Chisalau2, Cristina D. 
Parvanescu2, Sineta C. Firulescu2, Adina Turcu-Stiolica3, Andreea L. Barbulescu4, Stefan 
C. Dinescu1, Cristiana I. Dumitrescu4,  Roxana Mihaela Dumitrascu2, Criveanu Cristina1, 
Lucretiu Radu5,  Mihai Tusaliu6, Daniela Dumitrescu7 
 
1Craiova University of Medicine and Pharmacy, Department of Rheumatology, Craiova, Romania, 2Craiova 
University of Medicine and Pharmacy, Craiova, Romania, 3Craiova University of Medicine and Pharmacy, 
Department of Pharmaco-economics, Craiova, Romania, 4Craiova University of Medicine and Pharmacy, 
Department of Pharmacology, Craiova, Romania, 5Craiova University of Medicine and Pharmacy, Department 
of Nursing & Medical Care, Craiova, Romania, 6Carol Davila University of Medicine and Pharmacy, Bucharest, 
Romania, 7Craiova University of Medicine and Pharmacy, Department of Radiology, Craiova, Romania 
Abstract Background: the evaluation of cartilage thickness has become possible with new techniques such as 
musculoskeletal ultrasonography (US) and magnetic resonance imagining (MRI), making the evaluation of 
the treatment response and the progression of the disease more accurate. Objective: to evaluate the efficacy 
of a Symptomatic Slow Acting Drug for Osteoarthritis using both US and MRI for measuring cartilage 
thickness at baseline and after 1 year. Methods: The study included the clinical evaluation of 20 patients at 
baseline, at 6 and 12 months as well as imaging exams (US and MRI) at baseline and after 1 year. 
Measurements were performed in both knees, in lateral and medial condyles, and in the intercondylar area. 
After the baseline visit, patients underwent a SYSADOA treatment which included Harpagophytum 
procumbens (HPc) administered on a daily basis, in a specific regimen. Results and discussions: The US 
examination permitted the detailed evaluation of the femoral hyaline cartilage thickness, with statistically 
significant differences before and after treatment at the level of the medial compartment, both in the 
dominant (1.59±0.49 vs. 1.68±0.49, p=0.0013) and non-dominant knee (1.73±0.53 vs. 1.79±0.52, p=0.0106). 
The US and the MRI correlated well (r=0.63) and showed no radiographic progression in knee osteoarthritis 
after one year of treatment with specific SYSADOA. Moreover, the US showed improvement in the cartilage 
thickness of the medial compartment. Conclusions: The combination with HPc could increase the delay in 
the radiographic progression of the knee osteoarthritis, with improvement of femoral hyaline cartilage 
thickness in the medial and lateral compartment. The US might be an important tool in OA evaluation and 
monitoring. 
Keywords  chondroitin sulfate, glucosamine sulfate, Harpagophytum procumbens, ultrasonography, hyaline 
cartilage, knee osteoarthritis, MRI 
Highlights  The combination with HPc could be able to delay progression of the knee osteoarthritis. 
 US and MRI represent important techniques with comparable results on patients with 
osteoarthritis, but with the remark that US is a much cheaper and more accessible tool. 
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Introduction 
Osteoarthritis represents the most frequent type of 
articular involvement and is the result of altered metabolic 
processes at the level of the joint cartilage, leading to a 
higher rate of destruction relative to synthesis. The result 
is the thinning of the protective cartilage along with joint 
space narrowing, with consecutive pain and functional 
impairment in the early stages of the disease, as well as 
joint deformities and even ankyloses in later stages. 
The treatment for osteoarthritis includes both fast 
acting symptomatic drugs (analgesics, nonsteroidal anti-
inflammatory drugs) and slow acting drugs (SYSADOA – 
Symptomatic Slow Acting Drug for Osteoarthritis) – with 
a chondrotrophic and chondroprotective roles, such as 
glucosamine or chondroitin, involved in the balance 
between the synthesis and degradation of cartilage. The 
outcome is less pain and improved mobility and 
functioning at the joint; however, the effects tend to 
appear only after 6 months of treatment (1).   
EULAR 2003 guidelines position glucosamine and 
chondroitin at the maximum level of evidence for 
pharmacological actions in case of knee osteoarthritis, 
being classified as 1A for clinical studies and at level A of 
recommendation (2, 3). More recently, the 2018 EULAR 
update for the management of hand OA includes 
chondroitin and chondroitin compounds among the best 
nutraceuticals which may be used for the improvement of 
articular functioning (4). Most studies (over 300) 
evaluated products with a glucosamine/chondroitin rate of 
500/400mg, most frequent dosages involving 1500 mg of 
glucosamine and 1200 mg of chondroitin, but for a short 
period of time, such as 3 to 6 months (5-7). 
The American College of Rheumatology (ACR) 
conditionally (depending on the site of involvement) 
recommended avoiding glucosamine and chondroitin in 
cases of osteoarthritis (8), based mostly on the GAIT 
study that showed no difference in the joint space 
irrespective of the combination administered - 
glucosamine, chondroitin, celecoxib, the combination of 
glucosamine and chondroitin, or placebo (9). 
Thus, the evaluation of cartilage thickness has become 
a requirement in the evaluation of treatment response and 
disease progression with the new techniques such as 
musculoskeletal ultrasonography (US) or magnetic 
resonance imagining (MRI). Currently, although 
consensus is lacking, most studies recommend MRI as the 
gold standard imaging method in rheumatology, since it 
can visualize all articular and peri-articular structures in 
great detail (10, 11). US might identify and evaluate 
cartilage thickness, as a hypoechoic structure, superficial 
to cortical bone (12-15). 
Materials and Methods 
Objective 
The aim of our study was to evaluate the efficacy of a 
SYSADOA product that consists of a combination of 
500g glucosamine sulfate, 400mg chondroitin sulfate, 
10mg collagen type II and 40mg Harpagophytum 
procumbens per day (ed.), using both US and MRI to 
measure articular thickness. As a secondary objective, we 
proposed to confirm the level of agreement between US 
and MRI in cartilage thickness measurements. 
Patients and Methods 
This longitudinal prospective open study included 20 
patients, aged 40-75 years, diagnosed with knee 
osteoarthritis according to clinical and imaging criteria 
(16). Informed consent had been signed and medical 
history records were reviewed for previous joint disease 
or comorbidities. Patients underwent clinical evaluation, 
saving anamnestic and clinical data and establishing the 
stage of the disease using Kellgren and Lawrence criteria 
(17).  
Excluded patients were those with severe knee 
osteoarthritis (Kellgren & Lawrence stage 4), aged over 
75yr, with local trauma or in need for knee surgery, with 
inflammatory joint diseases or organ failure, with a 
change in the NSAID treatment in the past week, or with 
history of recent use (less than 2 months) of SYSADOA 
drugs. Pain was quantified on the VAS scale and 
functional impairment was assessed using the WOMAC 
osteoarthritis index and HAQ 20 item questionnaires (18). 
The study design included clinical evaluation at 
baseline, at 6 and 12 months, and imaging exams (US and 
MRI) at baseline and after 1 year. After the baseline visit, 
which included both clinical and imaging evaluations, the 
patients received the SYSADOA treatment which 
consisted of a combination of 500g glucosamine sulfate, 
400mg chondroitin sulfate, 10mg collagen type II, and 
40mg Harpagophytum procumbens administered daily 
after lunch, for 2 months, alternated with 2 weeks of 
pause. In case of pain, patients were allowed to use escape 
medication (500 mg to 3000 mg paracetamol). Patient 
adherence was evaluated by counting capsules returned at 
each visit. 
The ultrasound (US) evaluation  
The ultrasound (US) evaluation was performed by  
the same examiner, an expert in musculoskeletal 
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ultrasonography, using an ESAOTE Biomedica MyLab25 
machine, equipped with a 10-18 MHz broadband, linear 
array transducer. Each patient was evaluated in grayscale 
(GS), being positioned in a supine position with the knees 
fully flexed in order to examine the femoral hyaline 
cartilage, in both the short and long axis of the femur. The 
US was performed according to EULAR guidelines (19). 
The hyaline cartilage was identified as a hypoechoic line 
of varying thickness, which was lying on top of the 
hyperechoic femoral cortical bone, covered by a thin 
hyperechoic line, defined as cartilage interface. The 
measurements were performed in both knees with the 
transducer in transverse scan, in both lateral and medial 
condyles, and in the intercondylar area, assuring a sharp 
horizontal superficial hyperechoic demarcation of the 
cartilage (Figure 1).  
Cartilage thickness was recorded and measured in all 
three areas. Moreover, any irregularities in the cartilage 
and subchondral bone, and any change in the hypoechoic 
aspect of the cartilage or in the cartilage interface that 
might have been indicative of crystal arthropathies, were 
noted. The interpretation of all findings was based on 
OMERACT definitions for US pathology (20).  
The MRI examination 
The scans were performed by an experienced 
radiology technician and were analyzed by an expert 
radiologist, with over 10 years of experience in 
rheumatologic MRI scans, which were both blinded to US 
and clinical data.  The study was performed on a 1.5 T 
MR system (Siemens Magnetom Symphony, 1.5 T) 
equipped with CP Flex large coil. 
The positioning of the patient in the magnet was 
supine with feet forward; the image protocol consisted of: 
COR_T2_TIRM, SAG_SE_T1, SAG_PD_TSE_FS and 
AX_T2_ME2D. The sequence parameters were: on 
COR_T2_TIRM: TR/TE: 7160 / 77; SAG_SE_T1: 
TR/TE: 526/12; SAG_PD_TSE_FS: TR/TE: 3960/14; 
AX_T2_ME2D: TR/TE: 758/22. The vision field was 170 
mm and the slice thickness ranged between 0.5-1.5mm. 
The measurement of cartilage thickness was 
performed first, on the COR_T2_TIRM sequence at three 
sites: in the middle of the medial femoral condyle, of the 
lateral femoral condyle, and the intercondylar area. The 
same medial and lateral femoral condyles were measured 
on SAG_SE_T to confirm the results. 
Statistical analysis 
Statistical analysis was performed using Graph Pad 
Prism 5.00 and data were expressed as the mean ± 
standard deviation (SD) unless specified otherwise. The 
values of cartilage thickness in both US and MRI 
evaluations were analyzed using paired t-test to verify 
differences between dominant and non-dominant sides 
and non-paired t-test to compare different imaging 
methods. Pearson’s correlation coefficient and linear 
regression models assessed the possible correlation 
between US findings and variables such as age, HAQ, or 
WOMAC. The significance level was set at p  0.05. 
Results 
The baseline evaluation included 40 knees in 20 
patients (11 females and 9 males), with a mean age of 
59.3±9.12yo and mean disease duration at the time of 
inclusion of 7.35±3.45 years, ranging from to 2 to 15 
years. The mean VAS at baseline was 76±9.90 mm. 
The US evaluation at baseline revealed that cartilage 
loss was more significant in the medial compartment, 
especially when compared to the intercondylar area. Thus, 
cartilage thickness was significantly higher in the central, 
intercondylar area (1.944±0.68 mm) when compared to 
the medial compartment (1.50±0.46, p=0.0037). 
However, we did not find any statistically significant 
differences between the intercondylar area and the lateral 
compartment, but a tendency for higher values in cartilage 
thickness in the central area (1.944±0.68 vs. 1.708±0.53, 
p=0.127). We also did not find any differences between 
the dominant versus non-dominant knee. 
 
 
Figure. 1 A. Ultrasound GS short axis image of the 
femoral hyaline cartilage, with the knee fully flexed. 
B, C. T2-weighed MRI images of the knee, with 
visible femoral cartilage and measurements of 
condyles (B) and intercondylar area (C). 
Florentin A. Vreju et al. 
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The MRI measurements correlated well with the 
values of cartilage thickness obtained by means of US, 
especially for the medial compartment (r=0.63), 
suggesting that ultrasonography could be an important 
evaluation method for the femoral hyaline cartilage. The 
minimal cartilage thickness value was 0.9 mm through 
MRI and corresponded to the minimal thickness of 0.83 
mm measured through US, in the same patient. 
From the point of view of articular functionality, it 
seems that there is a strong correlation with cartilage loss 
in general and not with specific medial compartment 
cartilage thinning (r=0.98). On the other hand, disability 
index correlates better with cartilage thickness in the 
dominant knee (r=0.82).  
Imaging evaluation of treatment response after 1 year  
The US and MRI evaluation 1 year after treatment 
initiation with combined therapy included 17 patients, 
since 3 patients were lost at follow-up: one patient 
underwent knee surgery secondary to meniscus and 
anterior cruciate ligament lesions, and 2 patients decided 
to leave the study for subjective reasons, not related to 
medication. 
The MRI results showed a difference in the femoral 
hyaline cartilage thickness, both in medial and lateral 
compartments, with an improvement at this level after the 
treatment. Thus, in the medial compartment of the 
dominant knee, there was a higher difference between 
baseline and 1-year later visit, though still not statistically 
significance (p=0.09). Femoral cartilage thickness seems 
to improve after SYSADOA treatment, especially in the 
non-dominant knee (non-dominant, p=0.05 vs. dominant, 
p=0.08). 
There was no difference in cartilage thickness before 
and after treatment, in the intercondylar area, both for the 
dominant (1.316±0.289 vs. 1.30±0.288mm, p=0.824) and 
non-dominant knee (1.232±0.264 vs. 1.276±0.258mm, 
p=0.500). 
The US examination permitted detailed evaluation of 
the femoral hyaline cartilage thickness, with a statistically 
significant difference before and after treatment at the 
level of the medial compartment, both in the dominant 
(1.59±0.49 vs. 1.68±0.49, p=0.0013) and non-dominant 
knee (1.73±0.53 vs. 1.79±0.52, p=0.0106). The 
improvement was even more visible in the lateral 
compartment, without depending on the dominant/non-
dominant joint (Table I). 
   
Table I. US cartilage thickness evolution from baseline to one year 
 Medial compartment Intercondylar area Lateral compartment 
 
Dominant Non- dominant Dominant Non- dominant Dominant 
Non- 
dominant 
Baseline 1.59±0.49 1.73±0.53 1.97±0.66 2.07±0.62 1.86±0.51 1.80±0.53 
1 year 1.68±0.49 1.79±0.52 1.98±0.64 2.05±0.56 1.99±0.47 1.91±0.50 
p 0.0013 0.0106 >0.05 >0.05 0.0002 0.0010 
Discussions  
This study highlighted two important facts: one 
concerning novel possibilities for the treatment of knee 
osteoarthritis and the other related to the role of US in the 
evaluation of the femoral hyaline cartilage, compared to 
the gold standard represented by MRI. 
Multiple long-term studies have shown that 
glucosamine administration might delay the progression 
of knee osteoarthritis (21) and may even determine 
modifying changes in the course of the disease 
(reversion).  The study published in 2002 by Pavelka et 
al., which included 202 patients with knee osteoarthritis, 
showed that after the daily administration for 3 years of 
1500 mg of glucosamine or placebo, the progression of 
joint space narrowing was different (+0.04 vs. -0.19) (21). 
Regarding the clinical evaluation, the placebo group 
showed no significant difference, in comparison with the 
active treatment group (13). In 2003, Bruyere et al. 
published a study on 212 patients with knee osteoarthritis, 
with similar results, with the remark that patients with 
mild to moderate disease benefited more after 
glucosamine treatment (23). 
Most of those studies tested only trophic compounds 
(glucosamine, chondroitin), in monotherapy or 
combination, without analgesic or anti-inflammatory drug 
association. Actually, it was considered that one of the 
benefits of SYSADOA treatment was the NSAID and 
analgesic drug sparing, in order to limit their 
cardiovascular, renal, or gastrointestinal adverse effects. 
However, the fact that NSAIDs and even glucocorticoids, 
in some specific doses, might influence joint cartilage 
metabolism was not evaluated. NSAIDs, especially, seem 
to inhibit the proteoglycan synthesis by chondrocytes 
(24).  
An MRI versus ultrasonography study in the management of knee osteoarthritis 
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In the last years, there has been increasing evidence of 
the favorable effects of Harpagophytum procumbens on 
pain and inflammation as an alternative to NSAIDs, with 
an improved safety profile (25). The standardized daily 
extract of 60mg Harpagophytum procumbens seems to 
have a similar effect as selective COX-2 inhibitors, but 
with fewer adverse reactions. It also seems to have a 
chondroprotective role by inhibiting NO, TNF-α, 
interleukin 1-β, leukotriene formation, and matrix 
metalloproteinase (MMP), which are responsible for 
cartilage destruction. Nevertheless, the anti-inflammatory 
and chondroprotective actions could be explained by 
inhibition of lipid peroxidase (26).  
Although, the association of those drugs was known, it 
was based only on the individual therapeutic properties of 
each of these compounds, as there is only one study in the 
literature showing that the combination of glucosamine-
chondroitin-Harpagophytum procumbens could lead to 
the inhibition of MMP metabolism (27, 28).  
Our study shows an increased delay in the progression 
of osteoarthritis, by adding Harpagophytum procumbens 
to the known chondroprotective combination of 
glucosamine-chondroitin, leading to benefits even before 
the 3-year period of treatment. 
The other result of the study showed a high level of 
agreement between US and MRI measurements of 
cartilage thickness, both on condyles and intercondylar 
area, in accordance with previous studies (29). Similar to 
the study of Pradsgaard et al., we have found constantly 
higher values of cartilage thickness measured by MRI, 
compared to the US-measured ones, a fact that could be 
explained by the higher sound speed inside the cartilage, 
in comparison with other tissues (roughly 1696m/s vs 
1540m/s) (29). Pradsgaard et al. suggested multiplying 
the results of the US measurement by 1.10 in order to 
obtain an accurate cartilage thickness, a finding confirmed 
by our study. Thus, our study also revealed no differences 
in the speed of sound within cartilage when comparing 
the US results to the MRI results. Therefore, once again, 
US might prove an important and accessible tool in the 
diagnosis and evaluation of osteoarthritis, besides other 
inflammatory and non-inflammatory joint diseases (30, 
31). 
We are aware of the limitations of this work. Because 
participants were drawn from a single center, the study 
risks selection bias. Moreover, our study is not placebo-
controlled and is limited to the small number of patients 
evaluated by a single US examiner, but it can be 
considered a pilot for further extension research, with 
intra- and inter-reliability studies. 
Conclusions 
The combination of 500g glucosamine sulfate, 400mg 
chondroitin sulfate, 10mg collagen type II and 40mg 
Harpagophytum procumbens determined a delay in the 
radiographic progression of knee osteoarthritis, in all 
compartments, with improvement of the femoral hyaline 
cartilage thickness in the medial and lateral compartment, 
visible both through US and MRI imaging techniques. 
Furthermore, US and MRI represent important 
techniques, with comparable results in the diagnosis, 
evaluation, treatment, and monitoring of patients with 
osteoarthritis, but with the remark that US is a much less 
costly and more accessible tool which offers the 
possibility of multiple joint evaluation. 
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